VJHemOnc is committed to improving our service to you

IMW 2019 | Predicting MM progression

VJHemOnc is committed to improving our service to you

Mark Bustoros

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses how the use of genomic predictors in multiple myeloma (MM) allows for the greater stratification of patients and thus provides clinicians with an increased capacity to predict who is most likely to progress. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter